Skip to main content

Agreement with Redoxis AB

Glucox Biotech announceed today the signing of a contract with Redoxis AB for further studie on Glucox smal molecule NOX4 inhibitors.

Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase. Redoxis AB is a research company with focused research on autoimmune diseases and with a recognized competence in R&D related to NAD(P)H-oxidase based disease mechanisms. According to the contract Redoxis undertakes to, on a fee-for-service basis, further study the influence of Glucox´ small molecule NOX4 inhibitors on NAD(P)H-oxidase.

Comments (297)

Leave a Reply

Your email address will not be published.

Let's Shape the Future Together

Connect with Glucox Biotech to explore collaborative opportunities and discover our innovative research.